iCAD (NASDAQ:ICAD – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, May 15th. Persons interested in registering for the company’s earnings conference call can do so using this link.
iCAD (NASDAQ:ICAD – Get Free Report) last released its earnings results on Tuesday, March 12th. The technology company reported ($0.02) earnings per share for the quarter. iCAD had a negative net margin of 27.08% and a negative return on equity of 21.63%. The company had revenue of $4.74 million during the quarter.
iCAD Price Performance
ICAD opened at $1.41 on Wednesday. The stock’s 50 day simple moving average is $1.64 and its 200 day simple moving average is $1.55. The firm has a market cap of $37.18 million, a price-to-earnings ratio of -6.41 and a beta of 1.36. iCAD has a 1 year low of $1.05 and a 1 year high of $3.97.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
- Five stocks we like better than iCAD
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Garmin Navigates to New Highs Driven By Wearables Trend
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What Are Dividend Contenders? Investing in Dividend Contenders
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
